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Recent study in a group of German patients with SSc has implicated the SNP in the MCP-1 gene (−2518 A to G) as a factor of
susceptibility to SSc. Reﬂecting the need for replication of genetic association studies, we investigated if this SNP is associated with
SSc in another Caucasian population. MCP-1 −2518 A/G genotypes were determined using PCR-SSP in 46 SSc patients and in
449 healthy subjects, all unrelated and of Slovak (Slavonic) origin. The distribution of MCP-1 −2518 A/G genotypes complied
with the Hardy-Weinberg equilibrium both in patient and healthy control groups. There was no diﬀerence in MCP-1 −2518
∗G
allele frequency between SSc patients and healthy subjects (patients: 0.23; controls: 0.24; P>. 05). Furthermore, MCP-1 −2518
GG homozygotes were similarly represented among SSc patients and healthy subjects (P>. 05). The association of MCP-1 −2518
A/G SNP with SSc observed originally in German population was not replicated in the Slovak population.
Copyright © 2008 Zdenka Navratilova et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Systemic sclerosis (SSc) is a complex autoimmune disease
characterised by ﬁbrotic changes in the connective tissues of
skin and internal organs [1]. Aetiology of SSc is not clear
to date, however, polymorphisms in genes for inﬂammatory
mediators, tissue-matrix proteins, and growth factors have
been recently implicated in autoimmune and ﬁbrotic pro-
cesses in SSc [1–4].
In particular, chemokine (C–C motif) ligand 2 (CCL2)
has been identiﬁed in circulation and in lesions from
SSc patients [5–10]. This chemokine, also known as MCP
(monocyte chemoattractant protein)-1, is chemoattractant
for monocytes/macrophages and is also an inducer of colla-
genbiosynthesis[1,10,11].Ithasbeen,therefore,speculated
that MCP-1 upregulation may cause cellular accumulation
in SSc lesions [7, 8] and may be also responsible for massive
deposition of extracellular matrix proteins in SSc skin [1, 10,
11].
Recently, a single nucleotide polymorphism (SNP) in the
promoter region of the MCP-1 gene (−2518 A/G), whose G
variant may associate with increased MCP-1 gene transcrip-
tional activity [12], was investigated in German SSc patients
[13]. Overrepresentation of MCP-1 −2518GG homozygotes
among the patients implicated carriage of MCP-1 G allele as
a risk factor for SSc [13]. To date, this observation has not,
however, been conﬁrmed in other cohorts or populations. In
agreement with rules of performing association studies [14],
this study aimed at replication of the association between the
MCP-1 −2518 A/G SNP and systemic sclerosis in another
patient population of Caucasian origin, namely in Slavonic
population of Slovakia.
2. MATERIALS AND METHODS
2.1. Patientsandcontrols
46 patients with systemic sclerosis (SSc) were included
in the study (Table 1). In agreement with fundamental
requirements for replication of genetic association studies
[14], SSc patients enrolled in the present study were
classiﬁed, characterised, and subgrouped according to the2 Mediators of Inﬂammation
criteria of American College of Rheumatology [15]; similar
approach was applied also in the study under replication
[13]. Patients were unrelated individuals of Slovak origin
and were recruited in one tertiary referral centre (National
Institute of Rheumatic Diseases, Piestany, Slovak Republic).
The control population consisted of 449 healthy unrelated
volunteers recruited in nearby Bratislava (284 males/165
females, mean age ± SD, 49 ± 10 years), in which the
absence of any autoimmune disease was excluded by health
questionnaire and interview.
Informed consent for the anonymous usage of their
DNA for the purposes of this study was obtained from
all enrolled subjects. The study was performed with the
approval of relevant ethics committees in National Institute
of Rheumatic Diseases, Piestany and Medical Faculties in
Bratislava and Olomouc.
2.2. AssessmentofMCP-1 −2518single
nucleotidepolymorphism
Genomic DNA was extracted from peripheral blood leuko-
cytes by standard salting-out method. SNP MCP-1 −2518
(rs1024611) was genotyped by polymerase chain reaction
with sequence speciﬁc primers (PCR-SSP) as described
elsewhere [16]. Brieﬂy, standard and mutant alleles were
ampliﬁed in two separate reactions. The constant reverse
primer (5  TGA GTG TTC ACA TAG GCT TC 3 )w a su s e d
for ampliﬁcation with the forward speciﬁc primers either for
the standard allele A (5  GTG GGA GGC AGA CAG CTA 3 )
or for the mutant allele G (5  GTG GGA GGC AGA CAG
CTG 3 ). In both cases, the amplicon size was 175bp. Reac-
tion conditions and usage of internal controls, adopted from
phototyping methodology, are also described elsewhere[16].
2.3. Statistics
Hardy-Weinberg equilibrium was tested using a χ2t e s to f
observed and expected genotype frequencies. Diﬀerences
betweenallelic,genotype,andphenotype(carriage)frequen-
cies in patient and control groups were assessed by χ2t e s t
usingWoolf-Haldanecorrectionincasesofsmallnumbers.P
value <.05 was considered to be signiﬁcant. Statistical power
of the present study to replicate main result from the initial
Germanstudy[13](thediﬀerencebetweentheproportionof
MCP-1 −2518GG homozygotes in SSc patients and control
subjects)wasdeterminedaccordingtotheprotocoldescribed
elsewhere [17].
3. RESULTS
Distribution of alleles, genotypes, and phenotypes of MCP-1
−2518 A/G SNP in patients with SSc and control population
is presented in Table 2. The distribution of MCP-1 −2518
genotypes was in compliance with Hardy-Weinberg equilib-
rium in both patient and control groups (P>. 05). Statistical
power of present study to replicate observations originally
reported for the German population [13] reached 99%.
No signiﬁcant diﬀerences in distribution of MCP-1
−2518∗G allele were observed between patients with SSc
Table 1: Clinical characteristics of 46 patients with systemic
sclerosis.
Males/females 4 : 42
Age (mean, min-max) (y) 42 (6–61)
Diﬀuse SSc/limited SSc∗ 9/35
Lung involvement (lung ﬁbrosis) 33 (1)
Gastrointestinal involvement 19
Kidney involvement 4
Acral ulcers 14
Myositis 5
Acroosteolysis 14
Sj¨ ogren’s syndrome 6
Anti-DNA-topo I antibodies 18
Anticentromere antibodies 4
∗In 2 patients the information is not available.
and healthy controls (P>. 05). Furthermore, MCP-1
−2518GG homozygotes and MCP-1 −2518∗G allele carriers
were similarly represented among SSc patients and healthy
c o n t r o ls u b j e c t s( P>. 05).
Because diﬀerent phenotypes of SSc have been recently
thought not to necessarily share a common genetic back-
ground [4], we were further interested if MCP-1 −2518
A/G variants may be related to internal organ involvement
or limited/diﬀuse form of SSc in our patients. The GG
genotype was associated with GI aﬄiction (P = .007), when
the distribution of MCP-1 −2518 A/G SNP was compared
between the patients with GI involvement and healthy
controls. The allele and phenotype frequencies in patients
with the GI aﬄiction or the diﬀuse form of SSc did not diﬀer
from those in healthy controls (P>. 05). When the patients
with GI involvement were compared with patients without
the aﬄiction, we found no diﬀerence in the distribution of
MCP-1 −2518 SNP (P>. 05, Table 3). Furthermore, the
allele, genotype, and phenotype frequencies in patients with
limited SSc were similar to those observed in diﬀuse form of
SSc (Table 3). Similarly, MCP-1 −2518 SNP was not related
to the pulmonary (P>. 05, Table 3) or renal involvement in
our SSc patients (data not shown).
4. DISCUSSION
Despite an adequate methodical approach, the present study
did not reveal an association between MCP-1 −2518 A/G
single nucleotide polymorphism and systemic sclerosis in
Slovak population. Therefore, our data do not conﬁrm the
ﬁndings from German population [13] and do not support
hypothesis that MCP-1 −2518 A/G SNP is directly involved
in the genetic susceptibility to SSc.
To explore the association of MCP-1 −2518 A/G SNP
with susceptibility for SSc, our case-control study used the
same methodological strategy as the original report [13], but
importantly the size of the case group in our study was 2.5
fold bigger than the original one (46 versus 18). Moreover,
the statistical power of the current study to replicate the
initialobservationreaches99%.ThisvalueissuﬃcientlyhighZdenka Navratilova et al. 3
Table 2: Genotype, allele, and phenotype (carriage rates) frequencies of the MCP-1 −2518 SNP in Slovak patients with systemic sclerosis
and healthy controls compared with the data from German population according to the study by Karrer et al. [13].
Frequency Genotype Allele Phenotype
AA AG GG A G A G
Slovak patients (n = 46) 63.0 (29) 28.3 (13) 8.7∗ (4) 77.2 (71) 22.8+ (21) 91.3 (42) 37.0# (17)
Slovak controls (n = 449) 57.5 (258) 36.7 (165) 5.8 (26) 75.8 (681) 24.2† (217) 94.2 (423) 42.5 (191)
German patients (n = 18) 44.4 (8) 27.8 (5) 27.8§ (5) 58.3 (21) 41.7 (15) 72.2 (13) 55.6 (10)
German controls (n = 139) 51.1 (71) 42.4 (59) 6.5 (9) 72.3 (201) 27.7 (77) 93.5 (130) 48.9 (68)
Data are given as proportions (%) of particular genotype/allele/phenotype with their absolute number in parentheses. P values for comparison of allele,
genotype, and phenotype frequencies between the Slovak SSc patients and controls: +P = .81; ∗P = .67; #P = .51. P value for comparison of GG genotype
frequencies between the German SSc patients and controls [13]: §P = .02. P value for comparison of G allele frequencies between the Slovak and German
control subjects [13]: †P = .23.
Table 3: Genotype, allele, and phenotype (carriage rates) frequencies of the MCP-1 −2518 SNP in the subgroups of patients with systemic
sclerosis (SSc) according to the particular clinical manifestation of the disease (diﬀuse versus limited form, presence versus absence of lung
or gastrointestinal (GI) involvements).
Frequency Genotype Allele Phenotype
A A A G G G AGAG
Diﬀuse SSc (n = 9) 66.7 (6) 11.1 (1) 22.2 (2) 72.2 (13) 27.8 (5) 77.8 (7) 33.3 (3)
Limited SSc (n = 35) 62.9 (22) 31.4 (11) 5.7 (2) 78.6 (55) 21.4 (15) 94.3 (33) 37.1 (13)
Lung involvement (n = 33) 57.6 (19) 30.3 (10) 12.1 (4) 72.7 (48) 27.3 (18) 87.9 (29) 42.4 (14)
Without lung involvement (n = 13) 76.9 (10) 23.1 (3) 0.0 (0) 88.5 (23) 11.5 (3) 1.0 (13) 23.1 (3)
GI involvement (n = 19) 68.4 (13) 10.5 (2) 21.1 (4) 73.7 (28) 26.3 (10) 78.9 (15) 31.6 (6)
Without GI involvement (n = 27) 59.3 (16) 40.7 (11) 0.0 (0) 79.6 (43) 20.4 (11) 1.0 (27) 40.7 (11)
Data are given as proportions (%) of particular genotype/allele/phenotype with their absolute number in parentheses. P ≥ .05 for diﬀuse versus limited form
of SSc and presence versus absence of lung or gastrointestinal (GI) involvements.
inordertodetectthegeneticassociationdescribedinoriginal
study, because it exceeds 80% threshold [17].
One may argue that discrepant observations in North-
European and Eastern-European populations may be due
to diﬀerent ethnic background. However, there were no
diﬀerences in frequencies of the MCP-1 −2518 G allele and
also of GG homozygote between German and Slovak healthy
populations and further, these were similar to those reported
in other Caucasian populations [13, 18]. In this regard,
Slavonic and German populations also did not diﬀer in the
distribution of a spectrum of twenty-two cytokine SNPs
located across 1, 2, 4, 5, 6, 7, 12, 16, and 19 chromosomes
[19, 20].
Since patients in both centres were enrolled accord-
ing to uniﬁed international criteria, it is improbable that
discrepancies between these two studies were caused by
heterogeneous disease phenotypes. In our opinion, the
most straightforward explanation of the positive genetic
association reported in the original study may be the very
small sample size of its patient group (n = 18) that may
not reﬂect real distribution of MCP-1 −2518 A/G SNP
in German patients [13]. In support of this explanation,
also a recent study investigating a spectrum of chemokine
polymorphisms in non-Caucasian (Korean) population [2]
included more SSc patients than the original German study
[13] and similar to us, no relationship between the MCP-1
A/G SNP and disease in Koreans was observed [2].
Despite the number of SSc patients in our study was
much higher than in original report [13], in one particular
situation it may be considered as “suboptimal:” our study
may not be powerful enough to detect possible “true
association” in case that it would be much weaker than
observed in initial German study [13]. This situation could
occur if this MCP-1 polymorphism confers a risk to only
particular phenotype of SSc that is overpresented in German
patients [13], but minor or totally absent in Slovak patients
group. In this regard, German study recruited SSc patients
presenting with skin involvement while aﬀection of other
internal organs was not reported here [13]b yc o n t r a s tt oo u r
Slovak patients. Taking this into account, we can speculate
that MCP-1 −2518 A/G SNP may be related to a particular
phenotype of SSc.
Finally, from a geneticist’s point of view, the contradic-
tion between the present study and the initial observations
[13] can be explained by the presence of linkage disequi-
librium (LD). Although MCP-1 −2518 A/G has been the
most commonly investigated MCP-1 SNP, there are other
SNPs located in the MCP-1 gene [12]. Moreover, the data
on the functional signiﬁcance of MCP-1 −2518 A/G SNP
are not consistent [13, 16], and the investigated SNP is
not the only factor involved in regulation of MCP-1 gene
transcriptional activity [12]. It may be, therefore, speculated
that in setting of systemic sclerosis, the MCP-1 −2518∗G
allele represents a marker in linkage disequilibrium (LD)
with supposed “casual” allele located nearby. In this context,
theinvestigationsoftheroleforMCP-1genepolymorphisms
should be directed at wider range of SNPs and take into
account haplotype combinations [12].4 Mediators of Inﬂammation
In conclusion, this case-control study performed in
Slovak population does not provide further evidence for
recently formulated concept that MCP-1 −2518 A/G SNP is
involved in the genetic predisposition to systemic sclerosis as
a whole. However, it remains to be elucidated whether MCP-
1 −2518 A/G SNP may be in linkage disequilibrium with a
causative variant conferring susceptibility to SSc, which may
be located within the polymorphic CC chemokine genetic
cluster on the chromosome 17.
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